Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure
Brachytherapy · 2024-11 · 23 (6) · 727-736
DOI: 10.1016/j.brachy.2024.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2024-11. Verfasst von Yasushi Nakai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Nara, Japan; Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Brachytherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This study aimed to assess if prostate-specific antigen (PSA) threshold and PSA bounce are associated with oncological control after low-dose-rate brachytherapy (LDR-BT) alone or with external beam radiotherapy (EBRT), with or without androgen deprivation therapy (ADT), considering serum testosterone levels. METHODS: This study enrolled 944 prostate cancer patients treated at a single institution with LDR-BT alone or LDR-BT combined with EBRT, with or without ADT. The Fine-Gray hazard model was used to evaluate factors related to clinical failure, including experience of PSA bounce between baseline and 2, 4, or 7 years after LDR-BT and PSA value (0.1, 0.2, or 0.5 ng/mL) with normal testosterone levels at 2, 4, and 7 years after LDR-BT, respectively. RESULTS: Patients with normal testosterone levels and a PSA of 0.2 or 0.5 ng/mL at 2, 4, and 7 years after LDR-BT had a significantly better clinical failure free rate (CFFR) than those with PSA levels >0.2 or >0.5 ng/mL or low testosterone levels. Multivariate analysis revealed that PSA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nara Medical University, Nara, Japan; Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan.
- Department of Urology, Nara Medical University, Nara, Japan; Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan. Electronic address: sendo@naramed-u.ac.jp.
- Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan; Department of Radiation Oncology, Nara Medical University, Nara, Japan.
- Department of Urology, Nara Medical University, Nara, Japan.
- Department of Radiation Oncology, Nara Medical University, Nara, Japan.
Zitieren
APA
Nakai, Y., Tanaka, N., Asakawa, I., Onishi, K., Miyake, M., Yamaki, K., & Fujimoto, K. (2024). Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure. Brachytherapy, 23(6), 727-736. https://doi.org/10.1016/j.brachy.2024.09.003
Vancouver
Nakai Y, Tanaka N, Asakawa I, Onishi K, Miyake M, Yamaki K, et al. Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure. Brachytherapy. 2024;23(6):727-736. doi:10.1016/j.brachy.2024.09.003
BibTeX
@article{Nakai2024,
author = {Nakai, Yasushi and Tanaka, Nobumichi and Asakawa, Isao and Onishi, Kenta and Miyake, Makito and Yamaki, Kaori and Fujimoto, Kiyohide},
title = {Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure},
journal = {Brachytherapy},
year = {2024},
volume = {23},
number = {6},
pages = {727--736},
doi = {10.1016/j.brachy.2024.09.003}
}
EUVIMED